The US Food and Drug Administration today approved quizartinib (Vanflyta) for adults with acute myeloid leukemia (AML) that carries the FLT3-ITD genetic mutation. The FDA also approved the LeukoStrat ...
SAN DIEGO, May 19, 2020 /PRNewswire/ -- Invivoscribe to offer the LeukoStrat ® CDx FLT3 Mutation Assay as an FDA approved kit with analysis software. In 2017, Invivoscribe's LeukoStrat ® CDx FLT3 ...
Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® ...
Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, ...
Credit: Daiichi Sankyo. Vanflyta is expected to be available in the coming weeks. The Food and Drug Administration (FDA) has approved Vanflyta ® (quizartinib) in combination with standard cytarabine ...
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial Authors retain all ...
Note: This article has been updated to reflect the correct revised PDUFA date. FDA has added 3 months to the review timeline for quizartinib, an investigational therapy for the treatment of adult ...
An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results